Novartis AG ADR (NVS)vsSophia Genetics SA (SOPH)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
SOPH
Sophia Genetics SA
$7.87
+3.42%
HEALTHCARE · Cap: $688.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 65694% more annual revenue ($56.69B vs $86.17M). NVS leads profitability with a 22.5% profit margin vs -93.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SOPH
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for SOPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 27.2% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Trading at 8.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 27.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SOPH
The primary concerns for SOPH are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a value stock while SOPH is a growth play — different risk/reward profiles.
SOPH carries more volatility with a beta of 0.98 — expect wider price swings.
SOPH is growing revenue faster at 27.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 27/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) stands at the forefront of data-driven medicine, delivering advanced genomic and clinical data analytics that significantly enhance patient outcomes. Utilizing cutting-edge machine learning technologies, the company provides an integrated platform designed to help healthcare providers navigate complex genomic data, facilitating personalized treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with leading healthcare organizations, Sophia Genetics is well-positioned to transform the precision medicine landscape and solidify its role as a key player in the genomics industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?